皮肤T细胞淋巴瘤的免疫治疗相关进展

Immunotherapy in Cutaneous T Cell Lymphoma

皮肤T细胞淋巴瘤(CTCL)是一组异质性明显的非霍奇金淋巴瘤,最常见的是蕈样肉芽肿(MF)和Sézary综合征。CTCL早期病变进展缓慢,晚期则可累及多系统,预后较差,目前尚无有效的治疗方案。肿瘤的免疫疗法是指通过修复、增强宿主的免疫功能从而控制、清除肿瘤的一种治疗方法,治疗反应比传统疗法更为持久,目前已经在多种实体肿瘤中得到验证。本文就免疫治疗在CTCL中的研究进展作一综述。

Cutaneous T-cell lymphomas are a rare group of non-Hodgkin lymphomas with heterogeneous characteristics. The most common forms are Mycosis fungoides(MF) and Sézary syndrome(SS). Early stage disease follows a protracted course while advanced disease can involve multiple systems and has a poor prognosis. There is no effective treatment at present. Immunotherapy, which aims to repair and enhance the immune function of the host to control tumor progression and eradicate tumor cells, can produce a longer therapeutic response than traditional therapy. It has been applied in a variety of solid tumors. This article reviews the research progress of immunotherapy in CTCL.